Project: Non myocyte interplay as a novel platform for mechanistic insights and therapeutic approaches in ACM heart failure
| Acronym | ACM-HF (Reference Number: 2. JTC-2016_021) |
| Duration | 31/05/2017 - 30/05/2020 |
| Project Topic | Arrhythmogenic Cardiomyopathy (ACM) is a genetic cardiac disease, mainly affecting young people and athletes, characterized by heart failure and life-threatening arrhythmias. This project will study the cardiac cell interplay and develop a platform to test potential therapeutics, by exploiting an innovative patient-derived cell model combining CMs from induced pluripotent stem cells, Stromal cells and Inflammatory mediators (CSI model). This project is expected to elucidate mechanisms underlying ACM pathogenesis and to identify new disease targets and potential therapeutics. Engagement activities towards patient associations and advocacy groups will explain why the project questions and outcomes are relevant to patients and caregivers. |
| Network | ERA-CVD |
| Call | ERA-CVD Joint Transnational Call 2016 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Centro Cardiologico Monzino-IRCCS | Coordinator | Italy |
| 2 | Goethe University | Partner | Germany |
| 3 | INSERM, UMR-1048, Institut des Maladies Métaboliques et Cardiovasculaires | Partner | France |
| 4 | Fundació Clínic per la Recerca Biomèdica/Hospital Clínic | Partner | Spain |
| 5 | Leiden University Medical Center | Partner | Netherlands |
| 6 | Advanced Heart Failure and Transplantation Center | Partner | Slovenia |